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A
mAbstract
Psoriasis is a chronic and immune-mediated inflammatory skin disorder associated with
complex genetic susceptibility. Studies focused on the immunological mechanism have
revealed innate and adaptive immune activation in psoriatic lesions, including large
numbers of immune cells activated to produce many cytokines, chemokines,
and other inflammatory molecules. Knowledge on the genetic basis of psoriasis
highlights genetic susceptibility factors that play a crucial role in regulation of
immunity, epidermal proliferation, and skin barrier formation. Genetic susceptibility
factors affecting both the immune system and epidermis could predispose to
disease. Herein, we review the current knowledge on the role of genetic and
immunological factors in the development of psoriasis.
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Introduction
Psoriasis (MIM *177900) is a common, chronic, and immunologically mediated inflam-
matory skin disease that affects individuals at rates varying from 0.5% to 4.6% across
diverse ethnic populations (Lebwohl 2003). Symptoms typically develop in early adult-
hood, between the age of 15 and 25 years old (Henseler and Christophers 1985), but
individuals of all ages can be affected. The disease has certain distinct but overlapping
clinical phenotypes, including psoriasis vulgaris, which appears in approximately 90%
of all patients (Griffiths and Barker 2007), and at least 10% to 30% of patients develop
arthritis (Nickoloff and Nestle 2004; Ibrahim et al. 2009). Although psoriasis is rarely
life threatening, its morbidity and associated comorbidities have a severe negative im-
pact on the quality of life of the patients and also confer a certain socioeconomic bur-
den. Over the past few decades, substantial researches on the pathogenesis of psoriasis
have been a focus in the field of cutaneous disease. However, the mechanism of psoria-
sis pathogenesis likely involving the complex interplay among genetic, immunological,
and environmental risk factors (Nestle et al. 2009) has not been fully elucidated.
The concordance of monozygotic twins both suffering from psoriasis has been reported
to approximately 70%, and the sibling recurrence risk is estimated to range between 4 and
11 (Bhalerao and Bowcock 1998). Through a conventional family-associated on genetic
linkage approach, psoriasis-associated chromosomal regions have been identified. A major
genetic determinant of psoriasis, designated psoriasis susceptibility 1 (PSORS1), resides in2014 Sun and Zhang; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons
ttribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any
edium, provided the original work is properly credited.
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Cw6, which is as the most frequently detected allele in psoriasis (Veal et al. 2002; Nair et al.
2006). More recently, with the development of high-throughput genotyping platforms and a
comprehensive map of human haplotypes, genome-wide association studies (GWAS) have
evolved into a powerful tool for investigating the genetic architecture of human complex
diseases (Manolio et al. 2008). Taking advantage of GWAS, researchers have revealed many
novel and/or confirmed previous genetic loci associated with disease, and ongoing studies
are exploring additional genetic factors for associated with psoriasis.
The cellular features of psoriasis are epidermal hyperplasia and altered keratinocyte
differentiation, but substantial evidence implicates both innate and acquired immunity
in the disease pathogenesis (Gaspari 2006). The disease state is triggered by an acti-
vated cellular immune system, marked infiltration of T cells, dendritic cells (DCs), and
inflammatory cytokines in psoriatic skin lesions (Bowcock and Krueger 2005). As in
other immune-mediated diseases, such as rheumatoid arthritis (RA), Crohn's disease
(CD), multiple sclerosis (MS), and juvenile-onset diabetes, psoriasis is regarded as a T
cell-mediated autoimmune disease (Lowes et al. 2007). Therefore, it fits the definition
of an autoimmune disease (Davidson and Diamond 2001). Recent progress in the un-
derstanding of both the immunological and genetic basis of the disease has provided a
deep insight into the pathogenesis. In this review, we detail the recent advances in the
understanding of psoriasis pathogenesis, including the information regarding immuno-
logical factors, genetic aspects, and susceptibility genes shared with other autoimmune
or inflammatory diseases.
Immunological factors
Cells and molecules of immunity
Psoriasis is characterized by hyper-proliferation and aberrant differentiation of kerati-
nocytes (KCs), vascular abnormalities, and inflammatory infiltration. The cell types in
psoriatic plaques are involved in wound repair and/or are composed of the antigen-
presenting cells (APCs), including T lymphocytes cells, KCs, DCs, Langerhans cells
(LCs), and macrophages. The cellular innate and adaptive immune responses, especially
the activation of T cells, play a dominant pathogenic role in psoriasis (Krueger 2002;
Cai et al. 2012). Evidence for the central role of T lymphocytes has been found in ani-
mal models of psoriasis (Boehncke and Schon 2007), successful treatment of psoriasis
patients with cyclosporine A to inhibit T cell proliferation and cytokine production
(Mueller and Herrmann 1979) and specifically recruited T cell clones that permanently
involve the psoriatic inflammation (Vollmer et al. 2001). A dense infiltration is com-
posed of clusters of CD4+T cells and antigen-presenting DCs in the dermis, while
CD8+T cells and neutrophils are predominant in the epidermis of psoriatic lesions
(Lowes et al. 2007). The expression of activation markers by both CD8+T and CD4+T
cells has been observed in psoriatic lesions, and most of the T cells can also express the
memory cell antigens (Liu et al. 2007). Once the psoriatic plaques appear after T cell in-
filtration as the activated memory-effector T cells, cytokines, such as interleukin (IL)-2,
tumor necrosis factor-α (TNF-α), and interferon γ (IFN-γ) could be generated, which
stimulate an inflammatory response and change the characteristic of psoriasis (Austin
et al. 1999; Friedrich et al. 2000). An interrelation exists in that, CD4+T cells may
provide critical inductive and helper signals, while CD8+T cells are likely to be the
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Thus, in the epidermal compartment of psoriatic lesions, CD8+T cells could be acti-
vated and proliferated after CD4+T cells interact with antigen-presenting cells.
The changes in keratinocyte activation and proliferation that cause them to mature
too rapidly result in psoriasis. Keratinocytes in psoriatic lesions produce an array of
immune response-related proteins, such as the S100 proteins and intercellular adhesion
molecule 1 (ICAM-1), CD40, and HLA-DR, which attract leukocytes. The link is that
a positive feedback leads leukocytes to upregulate the S100 proteins (Bowcock and
Krueger 2005).Upon activation, KCs express a plethora of cytokines, chemokines, and
accessory molecules, transmitting both positive and negative signals to immune cells
(Albanesi et al. 2005). KCs also produce endothelial cell mitogens such as VEGF and
PDGF, leading to angiogenesis (Costa et al. 2007).
DCs are professional APCs involved in the regulation of the balance between immun-
ity and immunological tolerance. Cytokine profile studies have shown that dermal DCs
obtained from psoriatic lesions mediated a T cell response with high levels of IL-2 and
IFN-γ (Nestle et al. 1994). Plasmacytoid DCs (PDCs) have been identified in the psori-
atic skin and in uninvolved, healthy-looking psoriatic skin and were shown to be the
principal IFN-α-producing cells in early and developing psoriasis (Nestle et al. 2005).
Myeloid DCs, which are activated by PDCs and keratinocyte-derived cytokines, are also
accumulated in the psoriatic tissues (Zaba et al. 2009) and are believed to be required
for sustaining and amplifying the T cell inflammatory reaction (Chu et al. 2011). Studies
have shown that DCs may be the primary cell type that drives T-helper 17 (Th17) dif-
ferentiation in psoriasis through the production of IL-6 and IL-23 (Chu et al. 2011).
The crucial link between DCs and the IL-23/Th17 axis has been further strengthening
the suggestion that DCs obtained from psoriatic lesions could activate T cells to pro-
duce both IL-17 and IFN-γ (Zaba et al. 2009).
LCs reside in the basal and suprabasal layers of the skin and are closely associated
and interact with KCs through E-cadherin (Tang et al. 1993). A role for LCs has been
indicated in the pathogenesis of psoriasis (Cumberbatch et al. 2006), inducing the gen-
eration of distinct IL-22-producing Th22 cells infiltrating into the skin (Fujita et al.
2009). Macrophages can contribute to both epithelial-based and T cell-mediated path-
ways of inflammation in psoriasis (Clark and Kupper 2006). Macrophages interact with
KCs and secrete a variety of pro-inflammatory cytokines, such as TNF-α, IFN-α/β, IL-
1β, IL-6, IL-12, IL-10, and IL-18 cytokines, under various conditions (Wang et al.
2009a). Previous researches have suggested that the maintenance of psoriasiform skin
inflammation critically depends on efficient recruitment and activation of macrophages
with a sufficient release of TNF-α (Wang et al. 2006). As mentioned above, the cellular
features of psoriasis are epidermal hyperplasia and altered keratinocyte differentiation,
but mounting evidences have implicated both innate and acquired immunity in the dis-
ease progression of the disease (Nestle et al. 2009).
Several cytokines and chemokines, which induced keratinocyte proliferation, are
strongly expressed in the psoriatic skin. It has been well established by many experimental
studies that psoriatic inflammation mediated by T-helper 1 (Th1) cells (Uyemura et al.
1993; Schlaak et al. 1994). Characterization of cells and cytokines involved in the initiation
and maintenance of psoriasis showed elevated levels of IFN-γ, TNF-α, and IL-12, but not
of IL-4, IL-5, or IL-10, at both the mRNA and protein levels (Nestle et al. 1994; Schlaak
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IL-17 (Miossec et al. 2009) and IL-22 (Liang et al. 2006), have been implicated in psoriasis.
As a potent pro-inflammatory cytokine, IL-17 may stimulate keratinocytes to produce
neutrophil-attracting CXC chemokines (Nograles et al. 2008), as well as CCL20, which
draws CCR6+ cells into sites of inflammation (Harper et al. 2009). A mixed Th1 and Th17
inflammatory environment is found in the affected skin during the disease process (Lowes
et al. 2008). IL-23, which is composed of two subunits, a unique p19 subunit and a p40
subunit shared with IL-12 (Lee et al. 2004), represents a cytokine pathway that is differen-
tially increased in psoriatic lesions and is important in Th17 cells. IL-23 is overproduced
by DCs (Lee et al. 2004) and stimulates Th17 cells within the dermis to make cytokines in
psoriatic lesions. Recent studies have demonstrated that the IL-23/Th17 cell axis plays an
important role in the pathogenesis of psoriasis and presents a potential therapeutic target
(Di Cesare et al. 2009; Nakajima 2012). In addition to IL-23 and IL-17, IL-22 has also been
reported to induce cutaneous inflammation in an experimental murine model of psoriasis
and has also been shown to induce in vitro an inflammatory-like phenotype in vitro (Van
Belle et al. 2012). IL-22 is a member of the IL-10 cytokine family, which is primarily se-
creted by Th17 cells (Trifari et al. 2009). IL-22 is remarkably over-expressed in psoriasis,
most likely as a result of upregulated the levels of IL-23 and IL-6 (Boniface et al. 2007;
Zheng et al. 2007). TNF-α has been identified as a promising target molecule, with the
expression of TNF-α and its receptors enhanced in psoriasis (Ettehadi et al. 1994). The ef-
ficacy of TNF-α antagonists in the treatment of psoriasis suggests a central role of this fac-
tor in psoriatic plaque formation (Tobin and Kirby 2005).
In addition to T cell-derived cytokines, numerous antigen-presenting cells infiltrate
the psoriatic skin and produce inflammatory cytokines. A variety of chemokines and
chemokine receptors are present in psoriatic plaques. The percentages of peripheral
blood CD8+T cells expressing CXCR6 are higher in psoriasis patients than in healthy
individuals, and CXCL16-CXCR6 interactions mediate the homing of CD8+T cells to
psoriatic lesion (Gunther et al. 2012). In immune-pathogenesis of psoriasis, including
TARC (CCL17), MIG (CXCL9), IP10 (CXCL10), MDC (CCL22), and RANTES (CCL5),
as well as CXCR2, CXCR3, CCR4, CCL27-CCR10, MIP3α (CCL20), MIP3β (CCL19),
and CCR6, all involved in the inflammatory response of psoriasis (Nickoloff and Nestle
2004). Once chemokines bind to their respective receptors, they activate the cells to re-
lease of cytokines and growth factors to form a thick, erythematous scaly plaque.
Inflammation pathways
Psoriasis is a representative inflammatory skin disease, which is mediated through a cyto-
kine network. The activated DCs and T cells are central in its pathogenesis, creating a
? Type 1? inflammatory pathway, which links the activation of multiple inflammatory re-
sponses, such as the release of IFN-γ, IL-23, and IL-12 into the lesions (Lew et al. 2004).
This model is conceptually useful, but it accounts for only a small fraction of the patho-
genesis and cannot explain the total inflammatory character of psoriatic lesions.
Previous studies have shown that the activity of the p38 mitogen-activated protein
kinases (MAPKs) is increased in the psoriatic skin, supporting the potential role of
these kinases in the pathogenesis of psoriasis (Funding et al. 2007). The mitogen- and
stress- activated protein kinases 1(MSK1) are found to be involved in the phosphoryl-
ation of cyclic adenosine monophosphate response element-binding (CREB) protein in
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and TNF-α (Funding et al. 2006). Evidence shows that MAPK inhibitors are effective
anti-inflammatory drugs that reduce the synthesis of inflammation mediators at mul-
tiple levels and block pro-inflammatory cytokine signaling (Kaminska and Swiatek-
Machado 2008). It has therefore been confirmed that the pathway of the p38 MAPK/
MSK1 signaling pathway may play a potential role in psoriasis by producing pro-
inflammatory cytokines (Arthur and Darragh 2006).
Clearly, transcription factors, such as signal transducer and activator of transcription
1 and 3 (STAT1 and STAT3) and nuclear factor-κB (NF-κB), are activated in psoriasis.
Research on the transcriptional regulatory network for psoriasis shows that E2F tran-
scription factor 1 (E2F1), jun proto-oncogene (JUN), NF-κB 1, STAT1, STAT3, and SP3
are pivotal in the transcriptome network involved in the mechanism of psoriasis (Lu
et al. 2013). NF-κB is a key regulatory element in inflammatory pathways, in cellular
proliferation and differentiation, and in apoptosis as well as a crucial mediator in psor-
iasis (Goldminz et al. 2013). In a mouse model of psoriasis, NF-κB signaling is essential
for the pathogenesis and is strongly activated in psoriatic lesions (Wang et al. 2009b).
Compared to the non-psoriatic skin, the samples of the psoriatic skin demonstrate ele-
vated levels of activated, phosphorylated NF-κB (Lizzul et al. 2005). It is targeted by nu-
merous effector cells, including keratinocytes, Th17, and DCs, which respond to
extracellular stimuli consisting of TNF-α, plasmin, and TLRs (Goldminz et al. 2013). A
blockade of NF-κB signaling within various target cells leads to decrease production of
pro-inflammatory cytokines.
The Janus kinase (JAK)/STAT signaling pathway is well known to be involved in
many cellular processes including inflammation. The JAK/STAT pathway converts
cytokine signals into genomic responses that regulate proliferation and differentiation
of the immune cells (Kaminska and Swiatek-Machado 2008). JAK inhibitors may be a
new class of immunomodulatory agents with immunosuppressive, anti-inflammatory,
and antiallergic properties. When keratinocytes from the psoriatic skin were cultured, a
significant induction of the STAT1-induced transcriptional activity was stimulated with
either IFN-γ or IFN-α (Hald et al. 2013).STAT3 are involved in the upregulation of
keratin 17 (K17) expression induced by IL-22. Both STAT1 and STAT3 pathways are
involved in the upregulation of K17 expression induced by IL-17A, and this regulation
could be partially suppressed by STAT1 or STAT3 small interfering RNAs and inhibi-
tors (Shi et al. 2011). Taken together, these cellular signaling pathways, which have been
shown to be involved in the progression of psoriasis, present potential targets for new
prosiasis therapies.
Genetic factors
Linkage and candidate gene association study
Although psoriasis has a multifactorial etiology, it is strongly influenced by genetic fac-
tors (Lowes et al. 2007). Compared with the general population, a higher incidence of
the disease has been identified among first-degree and second-degree relatives of psor-
iasis. The risk of psoriasis is greater in monozygotic twins than in dizygotic twins,
confirming the genetic basis of the disease (Nestle et al. 2009). Prior traditional ap-
proaches, such as family-based linkage studies and population-based candidate gene as-
sociation studies, have had some success in identifying genetic risk factors. The major
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proximately 300 kb of the MHC class I region (Veal et al. 2002). Large-scale resequen-
cing has established HLA-C and its HLA-Cw*06 allele as the most likely PSORS1
candidate genes (Nair et al. 2006). Variants associated with the HLA-Cw*06 allele con-
tribute to one-third and one-half of the genetic susceptibility to psoriasis (Elder 2006)
and are determinant for the development of early-onset psoriasis (Zhang et al. 2003).
In addition to PSORS1, linkage analyses and association studies have highlighted
psoriasis loci on several other chromosomes outside of the MHC region, designated
PSORS2-PSORS10 (Bowcock and Krueger 2005; Perera et al. 2012). PSORS2 was local-
ized to the chromosomal region 17q25.3 in a family of European ancestry and has also
been observed in a Taiwanese family with multiple psoriasis-affected members (Jordan
et al. 2012). Two disease-causing CARD14 mutations in psoriasis identified by using
genomic capture and DNA sequencing suggest that the involvement of PSORS2 is due
to the mutation of this gene (Jordan et al. 2012). In the PSORS3 locus, on chromosome
4q (Matthews et al. 1996), evidence from an association study suggests a putative asso-
ciation between the interferon regulatory factor 2 (IRF2) and psoriasis, which indicates
that the IRF2 gene as a candidate for PSORS3 (Foerster et al. 2004). PSORS4 is in the
1q21 region (Matthews et al. 1996), where a common deletion (LCE3C_LCE3B-del) in
the late cornified envelope (LCE) cluster is associated with psoriasis (Coto et al. 2011).
The locus, PSORS5, on chromosome 3q21 has been found in family-based analysis
studies (Enlund et al. 1999). The cystatin A, zinc finger protein 148, and solute carrier
family 12 member A8 (SLC12A8) genes are proposed as candidate genes at the psoria-
sis susceptibility locus PSORS5 (Samuelsson et al. 2004; Huffmeier et al. 2005).
PSORS6, located at 19p13 (Lee et al. 2000), has been suggested to interact with PSORS1
(Huffmeier et al. 2009). PSORS7 at 1p (Veal et al. 2001), PSORS8 at 16q (Nair et al.
1997), and PSORS9 at 4q31-34 (Yan et al. 2007; Zhang et al. 2007) are all linked to
psoriasis. Although other susceptibility loci and genes have also been postulated, it is
difficult to replicate the results of these studies, a result of interethnic differences and
environmental variations.
Genome-wide association studies
GWAS have become an effective approach for identifying genetic variants associated
with disease risk (Price et al. 2010). To date, several large GWAS for psoriasis in both
the European and Asian populations have been performed (Nair et al. 2009; Zhang
et al. 2009; Ellinghaus et al. 2010; Huffmeier et al. 2010; Strange et al. 2010; Stuart et al.
2010; Sun et al. 2010; Tsoi et al. 2012) to identify novel susceptibility genes and mecha-
nisms associated with psoriasis with kinds of algorithms (Tables 1 and 2). It is worth
mentioning that the most highly significant associated single nucleotide polymorphisms
(SNPs) in different populations are localized in the MHC class I region, which encodes
the HLA molecules HLA-A, HLA-B, and HLA-C. The findings of GWAS pertaining to
psoriasis and psoriatic arthritis GWAS (Liu et al. 2008) demonstrate that the strongest
associated SNP alleles are highly correlated with the HLA-Cw*06, which is consistent
with the previously described involvement of the PSORS1 region. Through in-depth
analyses of the GWAS data, two additional susceptibility loci within the HLA region
have been shown to confer risk of psoriasis in both Chinese and European lineages
(Feng et al. 2009).
Table 1 The genetic loci associated with psoriasis identified by GWAS
Chromosomal Reported gene(s) SNP Context P value Odds ratio (95% CI) Population Ref.
1q21.3 LCE3B, LCE3D rs6677595 Intergenic 2.1 ? 10 −33 1.26 [NR] European (Tsoi et al. 2012)
LCE3D, LCE3A rs4085613 Intergenic 7 ? 10 −30 1.32 [1.25 to 1.39] Chinese (Zhang et al. 2009)
LCE3D rs4112788 Intergenic 3 ? 10 −10 1.29 [1.19 to 1.40] European (Strange et al. 2010)
1p36.23 SLC45A1, TNFRSF9 rs11121129 Intergenic 1.7 ? 10 −8 1.13 [NR] European (Tsoi et al. 2012)
1p36.11 RUNX3 rs7536201 nearGene-5 2.3 ? 10 −12 1.13 [NR] European
IL28RA rs7552167 Intergenic 8.5 ? 10 −12 1.21 [NR] European
rs4649203 Intergenic 7 ? 10 −8 1.13 [1.05 to 1.22] European (Strange et al. 2010)
3.91 ? 10 −12 1.16 [NR] Chinese (Cheng et al. 2013)
1p31.3 IL23R rs2201841 Intron 1.75? 10 −10 1.23 [NR] European (Elder 2009)
rs9988642 nearGene-3 1.1 ? 10 −26 1.52 [NR] European (Tsoi et al. 2012)
rs11209026 Missense 7 ? 10 −7 1.49 [1.27 to 1.74] European (Strange et al. 2010)
rs2201841 Intron 3 ? 10 −8 1.13 [NR] European (Nair et al. 2009)
2q24.3 IFIH1 rs17716942 Intron 1 ? 10 −13 1.29 [1.17 to 1.43] European (Strange et al. 2010)
2p16.1 FLJ16341, REL rs62149416 Intergenic 1.8 ? 10 −17 1.17 [NR] European (Tsoi et al. 2012)
REL rs702873 Intron 4 ? 10 −9 1.12 [1.04 to 1.20] European (Strange et al. 2010)
NR rs842636 Intron 6 ? 10 −6 1.15 [NR] European (Stuart et al. 2010)
2p15 B3GNT2 rs10865331 Intergenic 4.7 ? 10 −10 1.12 [NR] European (Tsoi et al. 2012)
5q33.3 PTTG1 rs2431697 Intergenic 1.11 ? 10 −8 1.20 [1.13 to 1.28] Chinese (Sun et al. 2010)
IL12B rs12188300 Intergenic 3.2 ? 10 −53 1.58 [NR] European (Tsoi et al. 2012)
rs2546890 ncRNA 1 ? 10 −20 1.54 [1.32 to 1.79] European (Ellinghaus et al. 2010)
rs3213094 Intron 5 ? 10 −11 1.39 [1.26 to 1.53] European (Strange et al. 2010)
rs2082412 Intergenic 2 ? 10 −28 1.44 [NR] European (Nair et al. 2009)
rs3213094 Intron 3 ? 10 −26 1.28 [1.23 to 1.35] Chinese (Zhang et al. 2009)



















Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)
5q33.1 TNIP1/ANXA6 rs3762999 Intergenic 4.55 ? 10 −18 1.23 [1.18 to 1.29] Chinese (Sun et al. 2010)
rs999556 Intergenic 3.83 ? 10 −21 1.25 [1.20 to 1.31] Chinese
TNIP1 rs17728338 Intergenic 1.4? 10 −13 1.56 [NR] European (Elder 2009)
rs2233278 UTR-5 2.2 ? 10 −42 1.59 [NR] European (Tsoi et al. 2012)
rs17728338 Intergenic 1 ? 10 −20 1.59 [NR] European (Nair et al. 2009)
IL13, IL4 rs1295685 Intergenic 3.4 ? 10 −10 1.18 [NR] European (Tsoi et al. 2012)
IL13 rs20541 Missense 5 ? 10 −15 1.27 [NR] European (Nair et al. 2009)
5q15 ERAP1 rs27432 Intron 1.9 ? 10 −20 1.2 [NR] European (Tsoi et al. 2012)
rs27524 Intron 3 ? 10 −11 1.13 [1.05 to 1.22] European (Strange et al. 2010)
rs151823 Intergenic 9.32 ? 10 −9 0.89 [0.85 to 0.92] Chinese (Sun et al. 2010)
5q15 LNPEP rs2303138 Missense 1.83 ? 10 −13 1.16 [NR] Chinese (Cheng et al. 2013)
6q25.4 EXOC2, IRF4 rs9504361 Intergenic 2.1 ? 10 −11 1.12 [NR] European (Tsoi et al. 2012)
6q25.3 TAGAP rs2451258 Intergenic 3.4 ? 10 −8 1.12 [NR] European
6q23.3 TNFAIP3 rs610604 Intron 3.07? 10 −10 1.23 [NR] European (Elder 2009)
rs582757 Intron 2.2 ? 10 −25 1.23 [NR] European (Tsoi et al. 2012)
rs610604 Intron 9 ? 10 −12 1.19 [NR] European (Nair et al. 2009)
6q21 TRAF3IP2 rs33980500 Missense 4.2 ? 10 −45 1.52 [NR] European (Tsoi et al. 2012)
rs458017 Missense 2 ? 10 −16 1.37 [1.22 to 1.54] European (Strange et al. 2010)
rs13196377 Intron 1.39 ? 10 −12 1.67 [1.45 to 1.93] European (Huffmeier et al. 2010)
rs13190932 Intron 8.56 ? 10 −17 1.83 [1.59 to 2.12] European
rs13210247 Missense 1.73 ? 10 −14 1.69 [1.48 to 1.94] European
rs33980500 Missense 1 ? 10 −16 NR European (Ellinghaus et al. 2010)
rs240993 Intron 5 ? 10 −20 1.25 [1.16 to 1.34] European (Strange et al. 2010)
6p21.33 HLA-C rs1265181 Intergenic 1.93 ? 10 −208 22.62 [NR] Chinese (Zhang et al. 2009)



















Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)
rs13191343 Intergenic 2.32 ? 10 −72 2.37 [2.16 to 2.61] European (Huffmeier et al. 2010)
rs12191877 Intergenic 4 ? 10 −32 2.79 [2.35 to 3.33] European (Ellinghaus et al. 2010)
rs10484554 Intergenic 4 ? 10 −214 4.66 [4.23 to 5.13] European (Strange et al. 2010)
rs12191877 Intergenic 1 ? 10 −100 2.64 [NR] European (Nair et al. 2009)
rs10484554 Intergenic 2 ? 10 −39 2.8 [2.40 to 3.30] European (Liu et al. 2008)
rs3134792 Intergenic 1 ? 10 −9 NR European (Capon et al. 2008)
HLA-B, HLA-C rs4406273 Intergenic 4.5 ? 10 −723 4.32 [NR] European (Tsoi et al. 2012)
HCP5 rs2395029 ncRNA 2 ? 10 −26 4.1 [3.10 to 5.30] European (Liu et al. 2008)
7p14.1 ELMO1 rs2700987 Intron 4.3 ? 10 −9 1.11 [NR] European (Tsoi et al. 2012)
8p23.2 CSMD1 rs7007032 Intron 3.78 ? 10 −8 1.16 [1.10 to 1.22] Chinese (Sun et al. 2010)
rs10088247 Intron 4.54 ? 10 −9 1.17 [1.11 to 1.23] Chinese
9q34.13 TSC1 rs1076160 Intron 6 ? 10 −6 1.09 [NR] European (Nair et al. 2009)
9q31.2 KLF4 rs10979182 Intergenic 2.3 ? 10 −8 1.12 [NR] European (Tsoi et al. 2012)
9p21.1 DDX58 rs11795343 Intron 8.4 ? 10 −11 1.11 [NR] European
10q22.3 ZMIZ1 rs1250546 Intron 6.8 ? 10 −7 1.1 [NR] European
11q24.3 ETS1 rs3802826 Intron 9.5 ? 10 −10 1.12 [NR] European
ZC3H12C rs4561177 nearGene-5 7.7 ? 10 −13 1.14 [NR] European
11q13.1 RPS6KA4, PRDX5 rs645078 Intergenic 2.2 ? 10 −6 1.09 [NR] European
12q13.3 STAT2, IL23A rs2066819 Intergenic 5.4 ? 10 −17 1.39 [NR] European
IL23A, STAT2 rs2066808 Intron 1 ? 10 −9 1.34 [NR] European (Nair et al. 2009)
IL23A rs2066807 Missense 1.9? 10 −5 1.33 [NR] European (Elder 2009)
rs2066808 Intron 2 ? 10 −7 1.49 [1.28 to 1.73] European (Strange et al. 2010)
12q13.2 RPS26 rs12580100 Intergenic 1 ? 10 −6 1.17 [NR] European (Stuart et al. 2010)
13q14.11 COG6 rs7993214 Intron 2 ? 10 −6 1.41 [1.22 to 1.61] European (Liu et al. 2008)



















Table 1 The genetic loci associated with psoriasis identified by GWAS (Continued)
14q13.2 NFKBIA, PSMA6 rs12586317 Intron 2 ? 10 −8 1.15 [NR] European (Stuart et al. 2010)
NFKBIA rs8016947 Intergenic 2 ? 10 −11 1.19 [1.11 to 1.27] European (Strange et al. 2010)
3.9 ? 10 −10 1.12 [NR] Chinese (Li et al. 2013)
16p13.13 PRM3, SOCS1 rs367569 Intergenic 4.9 ? 10 −8 1.13 [NR] European (Tsoi et al. 2012)
16p11.2 PRSS53, FBXL19 rs12445568 Intergenic 1.2 ? 10 −16 1.16 [NR] European
FBXL19, POL3S rs10782001 Intron 9 ? 10 −10 1.16 [NR] European (Stuart et al. 2010)
17q25.3 CARD14 rs11652075 Missense 3.4 ? 10 −8 1.11 [NR] European (Tsoi et al. 2012)
17q21.2 PTRF, STAT3, STAT5A/B rs963986 Intergenic 5.3 ? 10 −9 1.15 [NR] European
17q11.2 NOS2 rs28998802 Intron 3.3 ? 10 −16 1.22 [NR] European
rs4795067 Intron 4 ? 10 −11 1.19 [NR] European (Stuart et al. 2010)
NR rs1975974 Intergenic 1 ? 10-7 1.17 [NR] European
18q22.1 SERPINB8 rs514315 nearGene-3 5.92 ? 10 −9 0.87 [0.83 to 0.91] Chinese (Sun et al. 2010)
18q21.2 POL1, STARD6, MBD2 rs545979 Intergenic 3.5 ? 10 −10 1.12 [NR] European (Tsoi et al. 2012)
19q13.41 ZNF816A rs9304742 Intron 2.11 ? 10 −9 0.88 [0.84 to 0.92] Chinese (Sun et al. 2010)
19p13.2 ILF3, CARM1 rs892085 Intergenic 3.0 ? 10 −17 1.17 [NR] European (Tsoi et al. 2012)
TYK2 rs34536443 Missense 9.1 ? 10 −31 1.88 [NR] European
rs12720356 Missense 4 ? 10 −11 1.4 [1.23 to 1.61] European (Strange et al. 2010)
rs280519 Intron 4 ? 10 −9 1.13 [1.05 to 1.21] European
20q13.13 ZNF313 rs2235617 Intron 2 ? 10 −6 1.2 [1.11 to 1.30] European
RNF114 rs1056198 Intron 1.5 ? 10 −14 1.16 [NR] European (Tsoi et al. 2012)
ZNF313 rs495337 Cds-synon 1 ? 10 −8 1.25 [1.12 to 1.39] European (Capon et al. 2008)
20q13.12 SDC4 rs1008953 Intergenic 1 ? 10 −7 1.14 [NR] European (Stuart et al. 2010)
22q11.21 UBE2L3 rs4821124 Intron 3.8 ? 10 −8 1.13 [NR] European (Tsoi et al. 2012)























1q21.3 LCE3B, LCE3D rs6677595 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
LCE3D, LCE3A rs4085613 Plink 1.02, PCA, Cochran-Armtiage
trend test, Cochran-Mantel-Hanezel
stratification analysis
(Zhang et al. 2009)
LCE3D rs4112788 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
1p36.23 SLC45A1,
TNFRSF9
rs11121129 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
1p36.11 RUNX3 rs7536201
IL28RA rs7552167
rs4649203 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
PCA, PLINK 1.07, R, EIGENSTRAT,
Cochran-Armitage trend test
(Cheng et al. 2013)
1p31.3 IL23R rs2201841 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
rs9988642 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
rs11209026 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
2q24.3 IFIH1 rs17716942 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
2p16.1 FLJ16341, REL rs62149416 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
REL rs702873 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
NR rs842636 MACH version 1.0, Meta-analysis (Stuart et al. 2010)
2p15 B3GNT2 rs10865331 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
5q33.3 PTTG1 rs2431697 R, PCA, Cochran-Armitage trend
test, Heterogeneity tests
(Sun et al. 2010)
IL12B rs12188300 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
rs2546890 MACH v.1.0.16, MACH2DAT, gPLINK
v2.049, CopyCaller v1.0, METAL
(Ellinghaus et al. 2010)
rs3213094 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
rs2082412 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
rs3213094 Plink 1.02, PCA, Cochran-Armtiage
trend test, Cochran-Mantel-Hanezel
stratification analysis
(Zhang et al. 2009)
5q33.1 TNIP1/ANXA6 rs3762999 R, PCA, Cochran-Armitage trend test,
Heterogeneity tests
(Sun et al. 2010)
rs999556
TNIP1 rs17728338 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
rs2233278 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
IL13, IL4 rs1295685 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
IL13 rs20541 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
5q15 ERAP1 rs27432 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
rs27524 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
rs151823 R, PCA, Cochran-Armitage trend
test, Heterogeneity tests
(Sun et al. 2010)
5q15 LNPEP rs2303138 PCA, PLINK 1.07, R, EIGENSTRAT,
Cochran-Armitage trend
(Cheng et al. 2013)
6q25.4 EXOC2, IRF4 rs9504361 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
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Table 2 The algorithms of psoriasis GWAS (Continued)
6q25.3 TAGAP rs2451258
6q23.3 TNFAIP3 rs582757 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
rs610604 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
6q21 TRAF3IP2 rs33980500 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
rs458017 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
rs13196377 birdseed-v2 algorithm, MACH1,
Χ2 test, Cochran-Mantel-Haenszel
tests, PHASE
(Huffmeier et al. 2010)
rs13190932
rs13210247
rs33980500 MACH v.1.0.16, MACH2DAT, gPLINK
v2.049, CopyCaller v1.0, METAL
(Ellinghaus et al. 2010)
rs240993 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
6p21.33 HLA-C rs1265181 Plink 1.02, PCA, Cochran-Armtiage
trend test, Cochran-Mantel-Hanezel
stratification analysis
(Zhang et al. 2009)
rs13191343 birdseed-v2 algorithm, MACH1,
Chi-Square test, Cochran-Mantel-Haenszel
tests, PHASE
(Huffmeier et al. 2010)
rs12191877 MACH v.1.0.16, MACH2DAT, gPLINK
v2.049, CopyCaller v1.0, METAL
(Ellinghaus et al. 2010)
rs10484554 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
rs12191877 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
rs10484554 STRUCTURE, EIGENSTRAT, Cochran-Armitage
Test, R, Haploview 3.2
(Liu et al. 2008)
rs3134792 Haploview software, Fisher's exact test,
PLINK, I2 statistic
(Capon et al. 2008)
HLA-B, HLA-C rs4406273 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
HCP5 rs2395029 STRUCTURE, EIGENSTRAT, Cochran-Armitage
Test, R, Haploview 3.2
(Liu et al. 2008)
7p14.1 ELMO1 rs2700987 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
8p23.2 CSMD1 rs7007032 R, PCA, Cochran-Armitage trend test,
Heterogeneity tests
(Sun et al. 2010)
rs10088247
9q34.13 TSC1 rs1076160 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)





11q13.1 RPS6KA4, PRDX5 rs645078
12q13.3 STAT2, IL23A rs2066819 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
IL23A, STAT2 rs2066808 Χ2 statistic, logistic regression , MACH (Nair et al. 2009)
SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
12q13.2 RPS26 rs12580100 Imputation(MACH software version
1.0), Meta-analysis
(Stuart et al. 2010)
13q14.11 COG6 rs7993214 STRUCTURE, EIGENSTRAT, Cochran-Armitage
Test, R, Haploview 3.2
(Liu et al. 2008)
GJB2 rs3751385 R, PCA, Cochran-Armitage trend test,
Heterogeneity tests
(Sun et al. 2010)
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Table 2 The algorithms of psoriasis GWAS (Continued)
14q13.2 NFKBIA, PSMA6 rs12586317 Imputation(MACH software version 1.0),
Meta-analysis
(Stuart et al. 2010)
NFKBIA rs8016947 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
Cochran? Armitage trend test, Cochran?
Mantel? Haenszel stratification analysis,
PLINK 1.07, R 15.1
(Li et al. 2013)
16p13.13 PRM3, SOCS1 rs367569 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
16p11.2 PRSS53, FBXL19 rs12445568
FBXL19,POL3S rs10782001 Imputation(MACH software version 1.0),
Meta-analysis
(Stuart et al. 2010)





rs4795067 Imputation(MACH software version 1.0),
Meta-analysis
(Stuart et al. 2010)
NR rs1975974
18q22.1 SERPINB8 rs514315 R, PCA, Cochran-Armitage trend test,
Heterogeneity tests
(Sun et al. 2010)
18q21.2 POL1, STARD6,
MBD2
rs545979 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
19q13.41 ZNF816A rs9304742 R, PCA, Cochran-Armitage trend test,
Heterogeneity tests
(Sun et al. 2010)
19p13.2 ILF3,CARM1 rs892085 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
TYK2 rs34536443
rs12720356 SNPTEST, R, IMPUTE2, PHASE,
logistic regression
(Strange et al. 2010)
rs280519
20q13.13 ZNF313 rs2235617
RNF114 rs1056198 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
ZNF313 rs495337 Haploview software, Fisher's exact
test, PLINK, I2 statistic
(Capon et al. 2008)
20q13.12 SDC4 rs1008953 Imputation(MACH software version 1.0),
Meta-analysis
(Stuart et al. 2010)
22q11.21 UBE2L3 rs4821124 PLINK, minimac, IMPUTE2, PCA (Tsoi et al. 2012)
PCA, principal-component analysis.
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that are involved in various biological processes, including the IL-23/Th17 pathway
(Ellinghaus et al. 2010; Huffmeier et al. 2010; Nair et al. 2009; Strange et al. 2010),
NF-κB signaling (Nair et al. 2009; Strange et al. 2010; Stuart et al. 2010), epidermal cell
differentiation (de Cid et al. 2009; Sun et al. 2010; Zhang et al. 2009), MHC class I pro-
cessing (Strange et al. 2010; Sun et al. 2010), the ubiquitin pathway (Capon et al. 2008;
Sun et al. 2010), and Th2-type response (Nair et al. 2009) as well as genes with yet un-
known functions. As mentioned above, the functional role of IL-23-induced and Th17
cell-mediated chronic inflammation is highlighted in the immune-pathogenesis of psor-
iasis. In GWAS findings of both European and Chinese populations, different SNP al-
leles associated with psoriasis in and upstream of the IL12B gene and the IL23R gene
have been identified, confirming the role of the IL-23/Th17 axis in psoriasis pathogen-
esis (Cargill et al. 2007; Nair et al. 2009; Zhang et al. 2009). IL12B (encoding the p40
Sun and Zhang Applied Informatics 2014, 1:3 Page 14 of 21
http://www.applied-informatics-j.com/content/1/1/3subunit of IL-23 and IL-12) and IL23A (encoding the p19 subunit of IL-23) are hetero-
dimerize to form IL-23. The IL-23/Th17 pathway signaling could promote cellular im-
mune responses by strengthening of a subset of IL-17-expressing T cells (Bettelli et al.
2007) or dysregulation of expression ultimately resulting in psoriasis.
Several mediators of the NF-κB signaling pathways are linked to psoriasis (Goldminz
et al. 2013). As revealed by GWAS, TNFAIP3 (TNF-α-induced protein 3) and TNIP1
(TNFAIP3-interacting protein 1), the gene products of which modulate this pathway
show a strong association with the disease (Elder 2009; Nair et al. 2009). Genetic vari-
ants in the TRAF3IP2 (TRAF3-interacting protein 2),which encodes a protein involved
in IL-17 signaling, are implicated in psoriasis susceptibility (Ellinghaus et al. 2010;
Huffmeier et al. 2010). TRAF3IP2 interacts with tumor necrosis factor receptor-
associated factor (TRAF) proteins and either I-?B kinase or mitogen-activated protein
kinase to activate either NF-κB or Jun kinase (Ellinghaus et al. 2010). Encoding endo-
plasmic reticulum aminopeptidase 1 (ERAP1), located in 5q15 associated region, which
encodes an amino peptidase regulatory factor for the quality of peptides bound to
MHC class I molecules, is implicated in psoriasis in both European and Chinese popu-
lations (Strange et al. 2010; Sun et al. 2010). Compelling evidence shows that it exits
the interaction between the HLA-C and ERAP1 loci in the psoriasis pathogenesis
process. ERAP1 variants could influence psoriasis susceptibility in individuals who carry
the HLA-C risk allele (Strange et al. 2010).Variants of the gene encoding zinc-finger
protein 313 (ZNF313) are also associated with psoriasis as well (Capon et al. 2008).
ZNF313 has a similar role of as the ubiquitin ligase of TRAC-1 to regulate T cell activa-
tion. The present data also provide evidences that skin barrier function plays a role in
psoriasis susceptibility. A deletion polymorphism of two genes (LCE3C and LCE3B) is
associated with psoriasis in different populations (de Cid et al. 2009; Zhang et al. 2009).
The LCE genes encode the stratum corneum proteins of the cornified envelope, which
is important in epidermal terminal differentiation (Mischke et al. 1996). Genetic sus-
ceptibility variant(s) within the LCE genes may influence the development of psoriasis
by interrupting the terminal differentiation of keratinocytes. Collectively, the genetic
determinants could lead to dysregulation of innate and adaptive immunity and to epi-
dermal barrier dysfunction in disease process.
Common genetic factors in autoimmune or inflammatory diseases
To evaluate the relationship between psoriasis and autoimmune disease, the findings of
one retrospective study suggest that psoriasis patients are more likely to be diagnosed
with an autoimmune disease than individuals without psoriasis (Wu et al. 2012). Com-
mon autoimmune or inflammatory (immune-mediated) diseases, such as RA, CD, MS,
celiac disease (CeD), inflammatory bowel disease (IBD), ankylosing spondylitis (AS),
and systemic lupus erythematosus (SLE), are highly prevalent in psoriasis patients.
Psoriasis and psoriatic arthritis (PsA) are interrelated disorders that share pathophysio-
logical mechanisms. The occurrence of psoriasis in conjunction with chronic inflamma-
tory arthritis is range from 10% to 30% of individuals with the disease.
Many confirmed and nominally associated psoriasis susceptibility loci show a high
level of overlap with the associated loci of other autoimmune diseases. This marked
overlap of autoimmune disease susceptibility loci may occur when the same variants
contribute to multiple diseases or when different variants in the same gene confer
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autoimmune and inflammatory diseases (Makredes et al. 2009), sharing many suscepti-
bility genes between them (Table 3). Several associated genes are also implicated in
other immune-mediated disorders, notably CD (Ellinghaus et al. 2012), offering insights
into the postulated shared pathogenesis of CD and PS. In addition to psoriasis, IL23R is
associated with IBD, PsA, and MS (Duerr et al. 2006; Begovich et al. 2007; Liu et al.
2008), highlighting the functional role of the IL-23/Th17 axis in immune-mediated in-
flammatory and autoimmune processes. Furthermore, many genes involved in the NF-
κB pathway, such as TNFAIP3 and NFKB1A, are also linked to risk for other auto-
immune diseases (Fung et al. 2009; Han et al. 2009; Bowes et al. 2010; Li et al. 2013).
Although HLA-C remains the strongest susceptibility candidate gene in psoriasis, evi-
dences for an interaction between HLA-C and other autoimmune diseases have been
confirmed by GWAS (Raychaudhuri et al. 2012). These and other regions of genetic as-
sociation shared with autoimmune diseases indicate that psoriasis may have similar im-
mune mechanism and pathogenic pathways. However, common susceptibility genes
among different phenotypes suggest that genetic variation may influence the entire
pathways to increase the risk for multiple diseases.
Next-generation sequencing
Our understanding of the genetic basis of psoriasis has been rapidly advanced by
GWAS approach. More than 40 robust susceptibility loci have been identified and con-
firmed to be associated with psoriasis using this technique. However, most of theTable 3 Susceptibility genes in risk loci shared by autoimmune or inflammatory diseases
Region Reported gene
(s)
Biological annotations Autoimmune and inflammatory diseases
overlap
1p31.3 IL23R IL-23/Th17 axis PsV, AS, BD, CD, LE, UC
1p36.11 RUNX3 CD8+ T lymphocyte
differentiation
PsV, CD, AS, CeD
2q24.2 IFIH1 Interferon signaling pathway PsV, T1D, vitiligo
2p16.1 REL Rel/NF-κB family PsV, PA, CD, RA, CeD, IBD
5q33.3 IL12B Th1 cell differentiation PsV, CD, IBD, MS, PA, UC,
5q33.1 TNIP1 NF-κB pathway PsV, IBD, SS, SLE, myasthenia gravis
5q31.1 IL13 Th2 cell differentiation PsV, IBD, asthma, AD
5q15 ERAP1 MHC class I processing PsV, AS, BD
6q23.3 TNFAIP3 NF-κB pathway PsV, CeD, SLE, IBD, RA
6q21 TRAF3IP2 NF-κB pathway; IL-23/Th17 axis PsV, IBD, PA
6p21.33 HLA-C MHC class I processing PsV, CD, PA, CRD, SJS-TEN, vitiligo
10q22.3 ZMIZ1 Inhibitor of activated STAT PsV, MS, CD, vitiligo, CeD, IBD,
11q24.3 ETS1 Regulation of Th17 and B cells PsV, SLE, CD, RA
16p13.13 SOCS1 IL-7RA/IL-7 pathway PsV, MS, T1D
19p13.2 TYK2 IL-23/Th17 signaling PsV, MS, T1D, CD
22q11.21 UBE2L3 Ubiquitin-conjugating enzyme PsV, SLE, IBD, CeD, RA
(Using NHGR1 GWAS catalog data, http://www.genome.gov/gwastudies/). PsV, psoriasis vulgaris; PsA, psoriatic arthritis;
AD, atopic dermatitis; IBD, inflammatory bowel disease; AS, ankylosing spondylitis; BD, Behcet's disease; CD, Crohn's
disease; CeD, celiac disease; LE, leprosy; MS, multiple sclerosis; RA, rheumatoid arthritis; SLE, systemic lupus
erythematosus; SS, systemic sclerosis; T1D, type I diabetes; UC, ulcerative colitis; SJS-TEN, Stevens-Johnson syndrome and
toxic epidermal necrolysis.
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variants of these susceptibility genes, particularly those that are of low frequency and
rare, are largely refractory to the interrogation by GWAS. Therefore, such variants have
not been systematically investigated. With the development of technologies for next-
generation sequencing (NGS) technologies, such as exome sequencing analysis, the sys-
tematic investigation of coding variants is possibly. Recently, a large-scale sequencing
analysis of functional coding variants was performed to investigate the contribution of
functional coding variants to the genetic susceptibility of psoriasis in a Han Chinese
population, identifying seven common and low-frequency nonsynonymous variants
within known psoriasis susceptibility genes, including IL23R, GJB2, LCE3D, ERAP1,
CARD14, and ZNF816A, that are associated with psoriasis risk (Tang et al. 2013).Conclusions
The pathogenesis of psoriasis involves a complicated interaction between genetic and
immunological and environmental components. During recent years, there have been
great advances and tremendous achievements in immunity and genetic research on
psoriasis that have contributed to the understanding of the mechanism of psoriasis. It
is clear that Th1, Th17, and Th22 cells, which interact with each other, mediate the im-
munity response in disease development. Recent GWAS have identified a variety of
genetic components involving both the immune system and the epidermis that affect
psoriasis pathogenesis. Several genetic factors and pathways shared with autoimmune
and inflammatory (immune-mediated) diseases highlight a common mechanism in dif-
ferent diseases. However, a substantial proportion of the involved genetic factors have
yet to be identified, and it is difficult to clarify how these genetic factors and pathways
intersect and contribute to inflammation, proliferation, and altered differentiation in
psoriasis. Fine mapping and resequencing efforts, together with extensive functional
studies, are required to detect all potential causal variants for the susceptibility to psor-
iasis. Recent advances in next-generation sequencing technologies will enable the in-
creased understanding of the pathogenetic mechanisms and will position a number of
confirmed genes or pathways as potential targets for future therapeutic intervention.
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